Clinical trials: ATRIAL FLUTTER
Atrial Fibrillation, Atrial Fibrillation, Persistent
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia
- Trial name
- RESOLVE-AF (NCT05883631)
- Testing
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 400 people
- Sponsor
- Cortex
Atrial Fibrillation (AF), Atrial Flutter
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
The goal of this clinical trial is to compare the yield of clinically actionable arrhythmias through the end of indicated wear duration in Zio monitor and Heartnote patch ECG devices.
- Conditions
- Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT)
- Trial name
- Japan H2H (NCT07870837)
- Testing
- Application of ambulatory cardiac monitor
- Where
- 4 sites in Japan
- Volunteers
- 130 people
- Sponsor
- iRhythm Technologies, Inc.
Atrial Fibrillation, Atrial Flutter
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
- Trial name
- NCT00126061
- Testing
- Tedisamil sesquifumarate
- Where
- 26 sites in United States, Czechia and 3 more
- Sponsor
- Solvay Pharmaceuticals
Atrial Flutter
IntellaTip MiFi XP Ablation Catheter Trial
A study to assess the performance of a new catheter design for the treatment of Atrial Flutter.
- Trial name
- MiFi-CTI (NCT01730807)
- Testing
- IntellaTip MiFi XP Catheter
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Arrhythmias, Cardiac, Atrial Fibrillation and Flutter
Aino ECG Ambulatory Study
The study includes collection of data from patients referred to a therapeutic evaluation in Tays Sydänkeskus Oy (Heart Center Co, Tampere University Hospital) or another unit of Sydänkeskus (hereafter the Heart Hospital) due to…
- Trial name
- NCT05008601
- Testing
- Wrist-word optical heart rate and ECG measurement device
- Where
- Finland
- Volunteers
- 31 people
- Sponsor
- PulseOn Oy
Atrial Fibrillation and Flutter
Dielectric Tissue Imaging in Cavotricuspid Isthmus Ablation
This is a prospective, single center, non-randomized, open-label, single arm study in which we will gather data and physician input for the assessment and further development of the KODEX - EPD functions for assessing tissue…
- Trial name
- ERUCA (NCT04438395)
- Testing
- Cardiac ablation via catheter
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EPD Solutions, A Philips Company
Death, Sudden, Cardiac, Ventricular Fibrillation
DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.
To prospectively evaluate if the analysis of genetic polymorphisms can be used to identify patients at risk of ventricular tachycardia.
- Conditions
- Death, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Atrial Fibrillation
- Trial name
- DISCOVERY (NCT00478933)
- Testing
- Defibrillator, Dual Chamber ; Implantable, Blood sampling
- Volunteers
- 1,223 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Intensive Care Unit, Coronary Artery Bypass Grafting (CABG)
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight…
- Conditions
- Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
- Trial name
- MODIFY CSX (NCT06279793)
- Testing
- Fish Oil, Intravenous 0.9% Sodium Chloride
- Where
- 10 sites in Germany
- Volunteers
- 550 people
- Sponsor
- GCP-Service International West GmbH
Cavotricuspid Isthmus Dependent Right Atrial Flutter
LINEAR II - LME-159 Evaluation of a Multi-Electrode Linear Type Ablation Catheter
The Linear II study is a prospective, single center, non-randomized, interventional feasibility study with the purpose of assessing acute safety of the Multi-Electrode Linear Type Ablation Catheter and the performance of the…
- Trial name
- NCT02257060
- Testing
- Endocardial Ablation
- Volunteers
- 12 people
- Sponsor
- Biosense Webster, Inc.
Acute Heart Failure (AHF), Cardiac Arrhythmia
Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure
This prospective, multicenter, open-label, single-group exploratory clinical trial evaluates the clinical effectiveness of extended electrocardiographic monitoring with MEMO Patch Plus for detecting clinically significant…
- Trial name
- MMPP-HF (NCT07792772)
- Testing
- MEMO Patch Plus
- Where
- 3 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- HUINNO Co., Ltd
Atrial Fibrillation or Flutter
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
LGN-VN-003 is a prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial…
- Trial name
- RESTORE SR (NCT02454283)
- Testing
- Vanoxerine HCl
- Where
- 16 sites in United States, Bulgaria and 3 more
- Volunteers
- 41 people
- Sponsor
- Laguna Pharmaceuticals, Inc.
Arrhythmias, Cardiac
The MAGiC™ Cardiac Ablation European Study
The purpose of the first phase of this feasibility study is to gather safety and performance data on MAGiC to support European marketing approval.
- Trial name
- MAGiC-FESTPMCF (NCT06019845)
- Testing
- MAGiC™
- Where
- 4 sites in Denmark, Lithuania and 2 more
- Volunteers
- 150 people
- Sponsor
- Stereotaxis
Atrial Flutter
Cardiac Electrophysiological Study
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
- Trial name
- NCT00616629
- Testing
- AZD1305
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Atrial Flutter
Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation
The objective of the study is to demonstrate the safety and feasibility of the Adagio Cryoablation System is subjects with Paroxysmal (PAF), Persistent (PsAF) and Long-Standing Persistent Atrial Fibrillation.
- Trial name
- CryoCure2 (NCT02839304)
- Testing
- Cryoablation System
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 80 people
- Sponsor
- Adagio Medical
Atrial Flutter
A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
- Trial name
- Scene 2 (NCT00476112)
- Testing
- Vernakalant Injection 20 mg/mL
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Advanz Pharma
Atrial Fibrillation, Atrial Flutter
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
This study investigates if the early detection and treatment of supraventricular arrhythmia (SVA) may help to prevent the progression of the arrhythmia and improve the clinical outcome.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Atrial Tachycardia
- Trial name
- SETAM (NCT01108692)
- Testing
- Telecardiology
- Where
- 57 sites in France
- Volunteers
- 602 people
- Sponsor
- Biotronik France
Atrial Fibrillation, Arrhythmias, Cardiac
Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias
The Apple Heart Study (AHS) is a research study conducted to evaluate whether the Apple Heart Study App can use data collected on the Apple Watch to identify irregular heart rhythms, including those from potentially serious heart…
- Conditions
- Atrial Fibrillation, Arrhythmias, Cardiac, Atrial Flutter
- Trial name
- NCT03335800
- Testing
- Apple Heart Study App
- Where
- United States
- Volunteers
- 419,927 people, healthy volunteers welcome
- Sponsor
- Apple Inc.
Atrial Fibrillation, Atrial Flutter
DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation
Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes.
- Trial name
- CONSIDERING-AF (NCT05838781)
- Testing
- Risk prediction model, 14-days continuous ECG monitoring
- Where
- 2 sites in Sweden
- Volunteers
- 2,112 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Atrial Flutter
Assessment of the Sphere-9™ Catheter and Affera Mapping and Ablation System for Treatment of Atrial and Ventricular Arrhythmias
A prospective, single-arm, multi-center, safety and performance assessment of the Sphere-9™ Catheter and the Affera Mapping and RF Ablation System to treat Atrial Arrhythmias
- Conditions
- Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia
- Trial name
- NCT04211441
- Testing
- Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
- Where
- 2 sites in Czechia
- Volunteers
- 74 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb